Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
DiBenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Prevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based study. Hand (N Y). 2011 Jun 1;6(2):149-58.
Price C, Golden B, Harrington M, Konewko R, Wasil E, Herring W. Reducing boarding in a post-anesthesia care unit. Prod Oper Manag. 2011 May 1;20(3):431-41.